Assignee
CASSIOPEA S P A
IT·14 granted patents·5 pending applications·44 citations·filing 2013–2025
Top patents by PatentIndex Score
19 records- 0194US9486458B2Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivativesCASSIOPEA S P A·Filed 2015·Granted Nov 8, 2016·10 cites·24 claims
- 0293US10166245B2Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivativesCASSIOPEA S P A·Filed 2016·Granted Jan 1, 2019·7 cites·34 claims
- 0393US10159682B2Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivativesCASSIOPEA S P A·Filed 2016·Granted Dec 25, 2018·7 cites·20 claims
- 0493US2025387412A1Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivativesCASSIOPEA S P A·Filed 2025·Application pending·0 cites
- 0590US11213531B2High concentration formulationCASSIOPEA S P A·Filed 2020·Granted Jan 4, 2022·2 cites·16 claims
- 0690US10603327B2High concentration formulationCASSIOPEA S P A·Filed 2016·Granted Mar 31, 2020·3 cites·25 claims
- 0789US9433628B2Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivativesCASSIOPEA S P A·Filed 2013·Granted Sep 6, 2016·6 cites·24 claims
- 0887US12337002B2Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivativesCASSIOPEA S P A·Filed 2022·Granted Jun 24, 2025·0 cites·21 claims
- 0987US9895379B217alpha, 21-dihydroxypregnene esters as antiandrogenic agentsCASSIOPEA S P A·Filed 2015·Granted Feb 20, 2018·4 cites·15 claims
- 1087US2026000681A1Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivativesCASSIOPEA S P A·Filed 2025·Application pending·0 cites
- 1186US9211295B217 alpha, 21-dihydroxypregnene esters as antiandrogenic agentsCASSIOPEA S P A·Filed 2014·Granted Dec 15, 2015·5 cites·26 claims
- 1286US2024189324A1High concentration formulationCASSIOPEA S P A·Filed 2023·Application pending·0 cites
- 1382US11938141B2Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivativesCASSIOPEA S P A·Filed 2021·Granted Mar 26, 2024·0 cites·12 claims
- 1479US11883415B2High concentration formulationCASSIOPEA S P A·Filed 2021·Granted Jan 30, 2024·0 cites·18 claims
- 1578US10716796B2Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivativesCASSIOPEA S P A·Filed 2018·Granted Jul 21, 2020·0 cites·15 claims
- 1677US10980819B2High concentration formulationCASSIOPEA S P A·Filed 2019·Granted Apr 20, 2021·0 cites·20 claims
- 1775US11207332B2Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivativesCASSIOPEA S P A·Filed 2019·Granted Dec 28, 2021·0 cites·20 claims
- 1866US2019282589A1High concentration formulationCASSIOPEA S P A·Filed 2019·Application pending·0 cites
- 1964US2016303141A1CORTEXOLONE 17alpha-PROPIONATE FOR USE IN THE TREATMENT OF SKIN WOUNDS AND/OR ATROPHIC SKIN DISORDERSCASSIOPEA S P A·Filed 2014·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →